Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR445877
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAR445877 is a bi-functional fusion protein drug candidate under development by Sanofi for the treatment of advanced solid tumors, including colorectal cancer, non-small cell lung cancer, metastatic hepatocellular carcinoma (HCC), gastric cancer, and gastroesophageal junction adenocarcinoma. The molecule consists of an anti-PD1 antibody fused to the cytokine IL-15. Its mechanism of action involves blocking PD-1 to enhance T cell activity while simultaneously stimulating the proliferation and activation of natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), and memory T cells within the tumor microenvironment. This dual action aims to boost antitumor immune responses locally at tumor sites. SAR445877 is administered intravenously as a solution and is currently being evaluated in Phase 1/2 clinical trials both as monotherapy and in combination with other anticancer agents such as cetuximab[1][3][4][5][7].
- Other names
- anti-PD1/IL-15 fusion proteinanti PD1/IL-15 fusion protein SAR445877
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SAR445877.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR445877.